Abstract | PURPOSE:
Heterotopic ossification is a common complication after total hip arthroplasty. Non-steroidal anti-inflammatory drugs ( NSAIDs) are known to prevent heterotopic ossifications effectively, however gastrointestinal complaints are reported frequently. In this study, we investigated whether etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor that produces fewer gastrointestinal side effects, is an effective alternative for the prevention of heterotopic ossification. METHODS: We investigated the effectiveness of oral etoricoxib 90 mg for seven days in a prospective two-stage study design for phase-2 clinical trials in a small sample of patients (n = 42). A cemented primary total hip arthroplasty was implanted for osteoarthritis. Six months after surgery, heterotopic ossification was determined on anteroposterior pelvic radiographs using the Brooker classification. RESULTS: CONCLUSIONS:
|
Authors | Jaap J Brunnekreef, Paul Hoogervorst, Marieke J Ploegmakers, Wim H Rijnen, Berend W Schreurs |
Journal | International orthopaedics
(Int Orthop)
Vol. 37
Issue 4
Pg. 583-7
(Apr 2013)
ISSN: 1432-5195 [Electronic] Germany |
PMID | 23359100
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cyclooxygenase 2 Inhibitors
- Pyridines
- Sulfones
- Etoricoxib
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Arthroplasty, Replacement, Hip
(adverse effects)
- Cyclooxygenase 2 Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Etoricoxib
- Female
- Hip Joint
(diagnostic imaging, surgery)
- Hip Prosthesis
- Humans
- Male
- Middle Aged
- Ossification, Heterotopic
(etiology, prevention & control)
- Osteoarthritis, Hip
(surgery)
- Prospective Studies
- Pyridines
(administration & dosage, adverse effects, therapeutic use)
- Radiography
- Severity of Illness Index
- Sulfones
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|